March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 30, 2026

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

Conexiant

March 30, 2026

Neurofilament Levels Linked to AF Risk

Higher levels associated with stroke, death, and heart failure in long-term cohort

Conexiant

March 30, 2026

Extended Viral PCR: Does It Help?

Researchers evaluate whether extended viral PCR testing is associated with antibiotic use and length of stay in adult inpatients.

Conexiant

March 23, 2026

AI Model Differentiates BCC vs cSCC Subtypes

External validation identifies calibration shift in COBRA cohort.

Conexiant

March 23, 2026

MRI Identifies 3 Friedreich Ataxia Subtypes

Machine learning analysis of structural MRI reveals distinct patterns of neurodegeneration that vary in their association with disease severity

Conexiant

March 18, 2026

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

Conexiant

March 17, 2026

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.

Conexiant

March 17, 2026

Toward Smarter Diagnosis of Prosthetic Joint Infection

Artificial intelligence models show promise but face key validation and design limitations

Conexiant

March 17, 2026

Can Biomarkers Refine Psych Dx?

Emerging evidence suggests biologic signals may predict treatment response and improve outcomes.

KFF Health News